NASDAQ:ATAI Atai Life Sciences (ATAI) Stock Price, News & Analysis $2.30 +0.03 (+1.32%) Closing price 02/14/2025 04:00 PM EasternExtended Trading$2.33 +0.03 (+1.30%) As of 02/14/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Atai Life Sciences Stock (NASDAQ:ATAI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Atai Life Sciences alerts:Sign Up Key Stats Today's Range$2.26▼$2.4850-Day Range$1.18▼$2.5552-Week Range$1.03▼$2.85Volume6.60 million shsAverage Volume2.58 million shsMarket Capitalization$385.94 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingBuy Company OverviewAtai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Read More… Atai Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreATAI MarketRank™: Atai Life Sciences scored higher than 54% of companies evaluated by MarketBeat, and ranked 549th out of 957 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAtai Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAtai Life Sciences has only been the subject of 2 research reports in the past 90 days.Read more about Atai Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Atai Life Sciences are expected to grow in the coming year, from ($0.77) to ($0.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atai Life Sciences is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atai Life Sciences is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtai Life Sciences has a P/B Ratio of 1.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Atai Life Sciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.67% of the float of Atai Life Sciences has been sold short.Short Interest Ratio / Days to CoverAtai Life Sciences has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Atai Life Sciences has recently decreased by 2.08%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtai Life Sciences does not currently pay a dividend.Dividend GrowthAtai Life Sciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.67% of the float of Atai Life Sciences has been sold short.Short Interest Ratio / Days to CoverAtai Life Sciences has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Atai Life Sciences has recently decreased by 2.08%, indicating that investor sentiment is improving. News and Social Media2.9 / 5News Sentiment0.27 News SentimentAtai Life Sciences has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Atai Life Sciences this week, compared to 2 articles on an average week.Search Interest14 people have searched for ATAI on MarketBeat in the last 30 days. This is an increase of 180% compared to the previous 30 days.MarketBeat Follows3 people have added Atai Life Sciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Atai Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders31.20% of the stock of Atai Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 28.41% of the stock of Atai Life Sciences is held by institutions.Read more about Atai Life Sciences' insider trading history. Receive ATAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atai Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ATAI Stock News Headlinesatai Life Sciences announces pricing of $55M public offering of sharesFebruary 13 at 8:40 AM | proactiveinvestors.comAtai Life Sciences: Promising Pipeline and Upcoming Catalysts Drive Buy RatingFebruary 13 at 7:17 AM | tipranks.comLeaked Trump video exposes his secret stocksTen investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the policies Trump will put in place. Ten investments with the potential to return 10x or more… but only if you act right now.February 15, 2025 | Porter & Company (Ad)Atai Life Sciences 26.2M share Spot Secondary priced at $2.10February 13 at 2:32 AM | markets.businessinsider.comatai Life Sciences Announces Pricing of Public Offering of Common SharesFebruary 12 at 10:47 PM | globenewswire.comAtai Life Sciences announces $55M common shares offeringFebruary 12 at 4:29 PM | markets.businessinsider.comatai Life Sciences unveils $55M public offering to advance mental health treatmentsFebruary 12 at 4:15 PM | proactiveinvestors.comatai Life Sciences Announces Proposed Public Offering of Common SharesFebruary 12 at 4:01 PM | globenewswire.comSee More Headlines ATAI Stock Analysis - Frequently Asked Questions How have ATAI shares performed this year? Atai Life Sciences' stock was trading at $1.33 at the beginning of 2025. Since then, ATAI shares have increased by 72.9% and is now trading at $2.30. View the best growth stocks for 2025 here. How were Atai Life Sciences' earnings last quarter? Atai Life Sciences (NASDAQ:ATAI) issued its earnings results on Tuesday, August, 13th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.20. The business had revenue of $0.27 million for the quarter. When did Atai Life Sciences IPO? Atai Life Sciences (ATAI) raised $200 million in an initial public offering on Friday, June 18th 2021. The company issued 14,300,000 shares at $13.00-$15.00 per share. Credit Suisse, Citigroup, Cowen and Berenberg served as the underwriters for the IPO and Cantor, RBC Capital Markets and Canaccord Genuity were co-managers. Who are Atai Life Sciences' major shareholders? Atai Life Sciences' top institutional shareholders include AdvisorShares Investments LLC (0.19%), Barclays PLC (0.10%), XTX Topco Ltd (0.08%) and Diametric Capital LP (0.06%). Insiders that own company stock include Apeiron Investment Group Ltd, Life Sciences NV Atai, Florian Brand, Srinivas Rao and Anne Nagengast Johnson. View institutional ownership trends. How do I buy shares of Atai Life Sciences? Shares of ATAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Atai Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atai Life Sciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), CrowdStrike (CRWD) and ServiceNow (NOW). Company Calendar Last Earnings8/13/2024Today2/15/2025Next Earnings (Estimated)3/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATAI CUSIPN/A CIK1420529 Webwww.atai.net.cn Phone49-89-2153-9035FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$11.00 Low Stock Price Target$6.00 Potential Upside/Downside+291.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,220,000.00 Net MarginsN/A Pretax Margin-38,531.72% Return on Equity-65.75% Return on Assets-52.71% Debt Debt-to-Equity Ratio0.14 Current Ratio5.81 Quick Ratio5.81 Sales & Book Value Annual Sales$310,000.00 Price / Sales1,244.97 Cash FlowN/A Price / Cash FlowN/A Book Value$1.47 per share Price / Book1.56Miscellaneous Outstanding Shares167,800,000Free Float115,448,000Market Cap$385.94 million OptionableOptionable Beta1.22 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:ATAI) was last updated on 2/15/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTop Picks for Trump’s Pro-Crypto America10,000% Crypto Opportunities in 2025 27 of the brightest minds in crypto share exclusive intel… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atai Life Sciences Please log in to your account or sign up in order to add this asset to your watchlist. Share Atai Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.